Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth

Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth

Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.

Scope

*Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017

*Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rate

*Assessment of the leading cancer brands and drug classes to identify key success factors within this sector

*Quantification of the market size of the cytotoxic therapy cancer brands in the seven major pharmaceutical markets with the rest of world markets

Highlights

The cytotoxic therapy cancer brands market is currently worth just over $10 billion and is forecast to grow to sales of almost $15 billion. The launch of the antimetabolite brands, Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitadine; Celgene) in the EU and Japanese markets contributes to this growth.

As a class, DNA-interactive cytotoxic therapy cancer brands contributed the highest proportion of sales in 2007 with $4.3 billion. This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to overtake.

Twenty four companies are involved in the development of currently approved cytotoxic therapy cancer brands, over half of which have more than one cytotoxic brand on the market. Sanofi-Aventis leads with four out of the 25 cytotoxic brands marketed, which made a collective $4,176m for the company in the seven major markets in 2007.

Reasons to Purchase

*Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2007 to 2017

*Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth

*Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

18-Jul-08 Format: PDF & DataPack Pages: 259

Table fo Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions